From fat-loss fad to preventative medicine for a range of chronic health conditions that result from obesity and other metabolic conditions.

Over the last couple of weeks, I have received multiple requests for comment on a small speculative radiology software stock called 4D Medical (ASX: 4DX), in part because it announced on July 31, 2025 ...

Lovisa Holdings (ASX: LOV) delivered another year of strong global growth in FY 2025, setting the stage for further expansion going forward.

Currently, four analysts cover the stock (per Morningstar), and their median forecast is EPS of 27.7¢ in FY26 (vs 25.3¢ in FY25). Assuming no downgrades over the course of the year, that’s growth of ...

Why homelessness advocacy group Everybody's Home argues it makes sense, citing hundreds of millions in currently foregone tax revenue.

A company I have covered many times for this publication, Vysarn (VYS:ASX) reported their FY 2025 earnings on Friday, with headline numbers looking relatively strong off the back of what was a ...

A spate of recent Australian cases where AI use by lawyers has created false case citations heralds a new era of legal issues for courts.

How to spot future large cap shares among ASX small caps. We cover key signals, a case study – PME vs NXT – and a potential future large cap.